Related Experiment Video

Updated: Aug 14, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

Anti-viral treatment in patients with virus-induced cardiomyopathy

U Kühl1, M Pauschinger, W Poller

  • 1Department of Cardiology and Pneumology, Campus Benjamin Franklin, Charité University Medicine Berlin, Germany. uwe.kuehl@charite.de

Ernst Schering Research Foundation Workshop
|December 7, 2005
PubMed

Insights

Persistent viral infections in the heart (myocarditis) worsen cardiomyopathy and heart function. Early diagnosis and antiviral treatment, like INF-beta, may reverse cardiac damage and improve patient outcomes.

Area of Science:

  • Cardiology
  • Virology
  • Immunology

Background:

  • Viral persistence in the myocardium is linked to poor cardiomyopathy prognosis, reduced work capacity, and significant social costs.
  • Cytokine network imbalance and immune response defects may drive virus persistence and myocardial dysfunction progression.
  • Early diagnosis and treatment are crucial for potentially reversing cardiac impairment.

Purpose of the Study:

  • To investigate the clinical effects of antiviral treatment (INF-beta) in patients with viral cardiomyopathy.
  • To assess the potential for reversing cardiac dysfunction and wall motion abnormalities through virus elimination.

Main Methods:

  • Pilot study involving antiviral treatment with INF-beta.
  • Clinical evaluation of cardiac function and wall motion abnormalities before and after treatment.
  • Assessment of viral elimination and its correlation with clinical improvement.

Main Results:

  • Pilot data showed beneficial clinical effects from anti-viral treatment with INF-beta.
  • Ventricular dysfunction and wall motion abnormalities showed resolution following the elimination of causative viral agents.
  • Virus elimination and clinical improvement were observed even in dilated cardiomyopathy (DCM) patients with a long disease history.

Conclusions:

  • Anti-viral therapy, specifically INF-beta, demonstrates potential clinical benefits in managing viral cardiomyopathy.
  • Elimination of cardiotropic viruses can lead to the reversal of cardiac dysfunction and wall motion abnormalities.
  • Early and potentially even late-stage viral cardiomyopathy may be amenable to antiviral treatment strategies.

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...